Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 281 Show results per page	View Search Criteria \| Help With Results


1.		An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				CC-5013-MM-016 NCT00179647

Last Modified: 10/22/2008 First Published: 7/1/1999


2.		Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 70				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15


3.		Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 70				Other				UARK 2003-26 NCT00090493

Last Modified: 6/9/2008 First Published: 9/26/2007


4.		Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 and over				NCI				RPCI-I-72806 I 72806, NCT00536601


5.		In-Vivo Activated T-Cell Depletion to Prevent GVHD

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				18 to 75				Other				0705-20 IUCRO-0196 NCT00594308


6.		Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				19 to 70				Other				F080429003 UAB-0775, NCT00714259

Last Modified: 9/19/2008 First Published: 11/1/2002


7.		Phase III Randomized Study of Thalidomide and Prednisone as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 and over				NCI, Other				CAN-NCIC-MY10 NCT00049673, NCIC-MY.10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, MY10

Last Modified: 10/21/2008 First Published: 12/23/2003


8.		Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 75				NCI				FHCRC-1813.00 5666, NCT00075478

Last Modified: 9/10/2008 First Published: 4/23/2005


9.		Phase III Randomized Study of Melphalan and Prednisone With Versus Without Bortezomib in Older Patients With Newly Diagnosed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				65 and over				NCI, Pharmaceutical / Industry				UCLA-0409110-01 JJPRD-26866138-MMY-3002, NCT00111319

Last Modified: 10/24/2008 First Published: 6/8/2005


10.		Phase III Randomized Study of Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				NCI				CALGB-100104 CALGB-100104, ECOG-CALGB-100104, NCT00114101

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute